Eli Lilly announced plans for four new pharmaceutical manufacturing sites to produce domestic medicine production in the United States and make the nation the world's leader in pharmaceutical production.

Eli Lilly and Co. is in negotiations with several states and plans to announce the locations of four new manufacturing plants later this year.

In a press release, Lilly chair and CEO David A. Ricks said, “Lilly's optimism about the potential of our pipeline across therapeutic areas–cardiometabolic health, oncology, immunology and neuroscience–drives our unprecedented commitment to our domestic manufacturing build-out.

It comes as companies work to build goodwill with Trump, who has emphasized reshoring manufacturing to the U.S. and reducing reliance on foreign supply chains.

The pharmaceutical company expects the expansion will create thousands of jobs.

Pharmaceutical giant Eli Lilly announced Wednesday that it plans to invest roughly $27 billion in United States manufacturing more than doubling its investment over the past five years. The company said this will be the largest pharmaceutical manufacturing investment in United States history.

Eli Lilly said it plans to build three new plants in the United States to make the key ingredients used in pharmaceuticals, part of a doubling of its investment in manufacturing.

Eli Lilly is building four new manufacturing sites, the drug company announced Wednesday, and though the $27 billion price tag is hefty, that’s not the notable piece of the announcement. Perhaps the more interesting part is that the sites are being located in the U.

Eli Lilly and Company has announced plans to build four new pharmaceutical sites in the United States, according to a press release from Lilly. The positions are reported to be ‘high-wage.’ The company expects to create around 3,